Press Detail

PRESS RELEASE

Biotest increases sales by 11,5% compared to previous year

- Good interim results of R&D projects Civacir^(R) and Tregalizumab (BT-061)

- Building permission for capacity expansion in Dreieich granted

Dreieich, 12 November 2014. The Biotest Group was able to further increase its pace of growth recorded in the first half of the year in the first nine months of 2014. The Group generated revenue of EUR 409.9 million in the period between January and September 2014. This represents an increase of 11.5 % compared to the same period in the previous year (EUR 367.5 million).

Operating profit (EBIT) decreased compared to the same period in the previous year due to the substantial increase in expenses and amounted to EUR 35.3 million for the first nine months of 2014, 11.5 % below the EUR 39.9 million for the same period in the previous year. Low margin tender business, particularly in the Therapy segment, and higher costs for clinical trial material in the amount of EUR 4.0 million resulted in a decrease in EBIT. Charges of EUR 2.2 million incurred in expanding capacity also had a negative impact on earnings.
Production of Bivigam^(R) has been temporarily scaled down due to lower than anticipated sales of Bivigam^(R). This also had a negative impact on sales and profit in the first nine months of 2014, an effect that will also be seen in the fourth quarter.

In the first nine months of 2014, Biotest made good progress in current studies and development projects. On 9 November 2014 Biotest presented positive results from the first part of the pivotal phase III trial (no. 988) with Civacir^(R) at the AASLD conference in Boston, US A. Civacir^(R) is investigated for prophylaxis of hepatitis C re-infection following a liver transplantation. The study results show no re-infection in the treatment group receiving the highest Civacir^(R) dosage, whereas re-infection occurred in approximately 35% of the patients in the control group despite prior treatment with new virostatics. More than half of the planned patients have already been included in the trial and further suitable patients are being recruited at the participating study sites.

Patient recruitment has concluded for the TRE AT 2b (T-cell REgulating Arthritis Trial 2b, no. 986) clinical phase II b study of the monoclonal antibody tregalizumab (BT-061), which started in 2013. More than 300 patients have been enrolled in the double-blind, randomised, placebo-controlled study in 84 clinical sites in 14 countries. Treatment of the patients is going according to plan. In the main part of the trial, the treatment duration is 24 weeks. Patients who respond to the treatment can continue the therapy for a further six months in an extension phase. Biotest expects that the study endpoints can be assessed at the end of the first quarter of 2015. First results will then be published in the second quarter of 2015.

The financial result amounted to EUR - 3.0 million (same period in the previous year: EUR - 3.9 million). Earnings before taxes (EBT) came in at EUR 32.3 million for the Biotest Group compared to EUR 36.0 million for the same period in the previous year. Earnings after taxes (EAT) also decreased from EUR 24.0 million to EUR 19.3 million on an increased tax rate. Earnings per share were - also as a result of the increased number of shares by way of the capital increase in the summer of 2013 - EUR 1.46 compared to EUR 1.96 for the first nine months of 2013.

Outlook:

Despite the challenging environment, the Board of Management expects for 2014 a sales increase above 7 % and an operating result (EBIT) in the range of the previous year. The business development of the Biotest Group for the 2014 fiscal year will continue to be assessed positively.

The nine-month report is available on the company's website http://www.biotest.de/ww/en/pub/investor_relations/publications/quarterly_reports.cfm.The presentation for today's conference for analysts and journalists as well as an audio file is available for download from the website.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.000 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart